Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | PRKACA | P17612 | 5/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510725 | 0.79 | TTR (0.45) | LTA4HTSHRXDHSLC22A12TLR4 | |
| SCHEMBL2089155 | 0.79 | TLR4 (0.58) | LTA4HTSHRTLR4TLR2LMNA | |
| SCHEMBL2089157 | 0.79 | TLR4 (0.58) | LTA4HTSHRTLR4TLR2LMNA | |
| SCHEMBL6662274 | 0.77 | CHRNB2 (0.43) | ROCK2PRKACAROCK1DYRK1AMAP4K4 | |
| SCHEMBL2092808 | 0.76 | TLR4 (0.55) | LTA4HTSHRTLR4TLR2LMNA | |
| SCHEMBL2092809 | 0.76 | TLR4 (0.55) | LTA4HTSHRTLR4TLR2LMNA | |
| SCHEMBL1349632 | 0.76 | CHRNB2 (0.46) | ROCK2PRKACAROCK1DYRK1AMAP4K4 | |
| SCHEMBL1349631 | 0.76 | CHRNB2 (0.46) | ROCK2PRKACAROCK1DYRK1AMAP4K4 | |
| SCHEMBL10720353 | 0.75 | XDH (0.39) | ROCK2PRKACAROCK1DYRK1AMAP4K4 | |
| SCHEMBL1348492 | 0.74 | AKT1 (0.45) | ROCK2PRKACAROCK1DYRK1AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | claimed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | claimed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | ROCK2 1704/4885PRKACA 3822/4885ROCK1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.